Preliminary Results

About this update from Oxford Instruments Plc

[{"type":"text","content":"\n \n Oxford Instruments plc full-year results 2024/25 \n Stron g results and g ood momentum \n Strate g ic execution on track and sale of quantum business \n Oxford Instruments plc, a leading provider of high technology products and systems for industry and research, today (13 June 2025) announces its preliminary results for the 12 months to 31 March 2025. \n Summary \n \n \n \n \n \n \n \n   \n \n \n Adjusted 1 \n \n \n   \n \n \n Statutory \n \n \n \n \n \n \n \n 2025 \n \n \n 2024 \n \n \n OCC growth 2 \n \n \n 2025 \n \n \n 2024 \n \n \n \n \n \n \n \n Revenue \n \n \n £500.6m \n \n \n £470.4m \n \n \n +6.5% \n \n \n £500.6m \n \n \n £470.4m \n \n \n \n \n \n \n \n Operating profit \n \n \n £82.2m \n \n \n £80.3m \n \n \n +10.8% \n \n \n £39.2m \n \n \n £68.3m \n \n \n \n \n \n \n \n Operating profit margin \n \n \n 16.4% \n \n \n 17.1% \n \n \n \n \n \n 7.8% \n \n \n 14.5% \n \n \n \n \n \n \n \n Operating profit margin OCC \n \n \n 17.8% \n \n \n 17.1% \n \n \n +70bps \n \n \n \n \n \n \n \n \n \n \n \n \n \n Profit before taxation \n \n \n £83.4m \n \n \n £83.3m \n \n \n 8.3% \n \n \n £39.8m \n \n \n £71.3m \n \n \n   \n \n \n \n \n Basic earnings per share \n \n \n 112.4p \n \n \n 109.0p \n \n \n 3.1% \n \n \n 44.8p \n \n \n 87.7p \n \n \n \n \n \n \n \n Cash conversion 3 \n \n \n 89% \n \n \n 64% \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Net cash 4 \n \n \n £84.4m \n \n \n £83.8m \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Dividend per share 5 \n \n \n 22.2p \n \n \n 20.8p \n \n \n 6.7% \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n Highlights \n ·    Revenue exceeds £500m for the first time, up by 6.5% at OCC 5 , driven by: \n -      Good growth in semiconductor and materials analysis, offsetting continued weakness in healthcare & life science \n -      Strong performance across North America, Asia and Europe, with successful pivot to new markets in China, now complete \n -      Double-digit revenue growth from commercial customers (c.50% of revenue, up from 45% in 2024) as we leverage our strength in our priority technologies from academia to commercial and applied R&D \n ·    Adjusted operating profit of £82.2m, up 10.8% OCC, and adjusted operating profit margin of 17.8% OCC, up 70bps, supported by operational efficiencies and new, simplified Group structure: \n -      Imaging & Analysis: OCC margin 24.7%, up 60bps - in the upper range of medium-term guidance, reflecting early results in strategic action, and despite market headwinds in life science holding back growth and operating leverage \n -      Advanced Technologies: constant currency margin of 4.5%, up 360bps - fix and improve action plan on track, with continued double-digit growth in compound semi business scaling and quantum returned to profitability \n ·    Robust demand and resulting orderbook provide good visibility for year ahead \n ·    £84.4m net cash (2024: £83.8m) after £15.4m acquisition consideration; normalised cash conversion improved to 89% from 64% in 2024 \n ·    FX headwind of £8.5m on adjusted operating profit, largely due to USD weakening \n ·    6.7% increase in the total dividend to 22.2p (2024: 20.8p) 5 \n Sale of quantum business and £50m share buyback programme launched \n ·    Binding agreement to sell NanoScience, the Group's quantum business, for consideration of £60m, of which £3m deferred. One-off transaction costs expected to be £2m-£3m. \n o  Enables the Group to focus on businesses with strong growth and margin characteristics where it is best placed to deliver value for shareholders \n o  Accelerates progress to deliver the Group's medium-term margin targets \n ·    Strength of balance sheet and proceeds from the sale of NanoScience enable up to £50m share buyback programme which will commence shortly \n   \n \n Richard Tyson, Chief Executive Officer of Oxford Instruments plc, said: \n \"The Group has had a good year, reporting strong revenue, profit growth, and constant currency margin progression. It was also a year of significant progress with our strategic initiatives to improve our operational and commercial outcomes. We have turned around the profitability of our NanoScience business, and subsequently crystallised an attractive value through the sale of the business for £60m, announced this week. The sale is in line with our strategy to focus and invest in the best areas of opportunity to grow the Group and create value for shareholders, and accelerates our progress to our medium-term margin targets. I am really pleased with the agility and performance of the whole Oxford Instruments team as they have responded to the new strategy and navigated the current market environment. \n \"This year's results demonstrate the benefits of the long-term drivers of our business model, founded on the growth dynamics in the markets where we operate, and the demand for our market-leading products and solutions. Looking ahead, whilst acknowledging the level of macro uncertainty, we have a strong and more focused business; there is a lot we can control, and we are well placed to mitigate any direct impact from tariffs. There are further benefits to be realised from our strategic initiatives to transform the business, and our revenue visibility is healthy. Our strong balance sheet, and the proceeds to come from the sale of our quantum business, allow us to return capital to shareholders via a share buyback that we've also announced this week. We are confident that our differentiated higher margin business will continue to deliver attractive profitable growth.\"   \n Notes \n 1.     Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non ‑ recurring items, and the mark-to-market movement of financial derivatives. A full definition of adjusted numbers can be found in the finance review and Note 2. \n 2.     Organic constant currency (OCC). References to year-on-year movements and margin percentages are shown at OCC or constant currency (CC) as appropriate. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme. \n 3.     Normalised cash conversion measures the percentage of adjusted cash from operations to adjusted operating profit, as set out in the finance review. \n 4.     Net cash includes total borrowings, cash at bank and bank overdrafts but excludes IFRS 16 lease liabilities, \n 5.     Proposed dividend per share, to be confirmed at the annual general meeting on 28 July 2025. \n   \n The financial information in this preliminary announcement has been prepared in accordance with UK adopted international accounting standards. The Group has applied all accounting standards and interpretations issued relevant to its operations and effective for accounting periods beginning on 1 April 2024. The UK adopted IFRS accounting policies have been applied consistently to all periods. \n LEI: 213800J364EZD6UCE231 \n   \n Oxford Instruments management will present its full-year results at Deutsche Numis, 45 Gresham Street, London EC2V 7BF, to analysts and investors at 10:00 today (13 June 2025). The presentation will be streamed live at https://brrmedia.news/OXIG_FY24/25 and a recording will be made available later today at www.oxinst.com/investors/financial-reports-and-presentations . \n The financial information for the year ended 31 March 2025 does not constitute statutory accounts as defined in sections 435 (1) and (2) of the Companies Act 2006. The auditor has reported on these accounts; their report was unqualified, did not include a reference to any matters to which the auditor drew attention by way of emphasis of matter and did not contain a statement under section 498 (2) or (3) of the Companies Act 2006. Statutory accounts for the year ended 31 March 2024 have been delivered to the Registrar of Companies and those for 2025 will be delivered following the Company's 2025 Annual General Meeting. \n Enquiries: \n   \n \n \n \n \n Oxford Instruments plc \n Richard Tyson, Chief Executive Officer \n Paul Fry, Chief Financial Officer \n   \n \n \n \n \n \n \n \n Stephen Lamacraft, Head of Investor Relations \n \n \n 07776 433916 \n s [email protected]   \n   \n \n \n \n \n MHP Group \n Katie Hunt/Tim Rowntree/Veronica Farah \n \n \n 07710 117517 \n [email protected]   \n   \n \n \n \n \n   \n   \n Notes to Editors \n   \n About Oxford Instruments plc \n Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductor, and healthcare & life science. \n Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. \n Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. \n Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). \n For more information, visit www.oxinst.com   \n Cautionary statement \n Certain statements in this announcement constitute, or may be deemed to constitute, forward-looking statements, projections and information (including beliefs or opinions) with respect to the Company and its subsidiary undertakings (\"the Group\"). An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They include, without limitation, statements regarding the Group's future expectations, operations, financial performance, financial condition and business. Such forward looking statements are based on current expectations and are subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from any expected future results in forward-looking statements. These risks, uncertainties include, among other factors, changing economic, financial, business or other market conditions. These and other factors could adversely affect the outcome and financial effects of the plans and events described in this announcement. \n Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules, Disclosure and Transparency Rules of the Financial Conduct Authority) no undertaking is given by the Group to update any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. \n This announcement has been prepared for the Group as a whole and therefore gives greater emphasis to those matters which are significant to the Group when viewed as a whole. \n Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this announcement. \n   \n Chief Executive Officer's Review \n I am pleased to report on an excellent full-year performance for Oxford Instruments. The actions we have taken to simplify the Group, improve commercial execution and realign our regional presence have resulted in strong growth in revenue and profit, and increased margins in both divisions. As signalled at half year, our targeted actions underpinned a strong second half performance, a particularly encouraging achievement in the context of a challenging geopolitical and macro environment. \n Demand for our market-leading technology, led by commercial customers, has resulted in strong double digit revenue growth in both compound and silicon semiconductor markets, and continued growth in materials analysis applications, which together have more than offset ongoing weakness in healthcare and life science. \n With good growth in orders and a robust order book, we have good visibility of planned revenues for the coming year, with order book to revenue ratios in line with historical patterns . We have mitigated the direct impacts of tariffs on existing orders through positive engagement with customers. With key semiconductor product lines currently exempt from the 10% US universal tariff, and with further mitigating actions at our disposal, we are confident we can continue to navigate this dynamic situation. \n \n \n \n \n Group \n \n \n 2025 \n \n \n 2024 \n \n \n growth \n \n \n OCC growth 1 \n \n \n \n \n Orders \n \n \n £463.7m \n \n \n £459.1m \n \n \n +1.0% \n \n \n +0.9% \n \n \n \n \n Revenue \n \n \n £500.6m \n \n \n £470.4m \n \n \n +6.4% \n \n \n +6.5% \n \n \n \n \n Adjusted 2 operating profit \n \n \n £82.2m \n \n \n £80.3m \n \n \n +2.4% \n \n \n +10.8% \n \n \n \n \n Adjusted 2 operating margin \n \n \n 16.4% \n \n \n 17.1% \n \n \n (70bps) \n \n \n \n \n \n \n \n OCC adjusted operating margin \n \n \n 17.8% \n \n \n 17.1% \n \n \n \n \n \n +70bps \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n Statutory operating profit \n \n \n £39.2m \n \n \n £68.3m \n \n \n \n \n \n \n \n \n \n \n Statutory operating margin \n \n \n 7.8% \n \n \n 14.5% \n \n \n \n \n \n \n \n \n \n \n   \n 1.   For definition refer to note above.  \n 2.      Details of adjusting items can be found in note 2 to the financial statements.   \n   \n The outcomes we have achieved reinforce our confidence in our ability to achieve the mid-term outcomes outlined in June 2024, which are as follows: \n ·    Organic revenue growth of 5-8% CAGR \n ·    Adjusted operating margin improvement to 20%+ \n ·    Cash conversion of over 85% \n ·    Continuing to invest in growth, including 8-9% on R&D \n ·    Strong return on capital employed (currently 27%) \n ·    Selective acquisitions bringing complementary capabilities. \n Positive strategic and operational progress \n As we set out in June 2024, our exceptional technology, strong talent base, well-distributed regional infrastructure and exposure to attractive markets give us a strong platform from which to grow, as well as providing valuable resilience to external dynamics. \n We highlighted then the significant opportunities ahead - and the fact that to capture them in full and achieve industry-leading margins, we needed to structure Oxford Instruments differently. \n A key focus of the year, therefore, was to simplify and streamline the Group, reconfiguring it into two new divisions, each with separate and distinct characteristics and opportunities. Both divisions have delivered strong progress. Our strategic actions to target enhanced growth and profitability through a customer-first approach have gained real traction, and have started to generate many of the outcomes we set out to achieve. \n In Imaging & Analysis , which represents 66% of the Group's revenue, and 93% of profit, our actions to integrate multiple business units and drive operational excellence have enabled the division to improve on an already strong position. The resulting synergies, cost reductions and productivity enhancements have supported the delivery of a 60bps improvement in OCC margin to 24.7%, at the upper end of our medium-term guidance of 23-25%. Ongoing demand remains strong, with our semiconductor and materials analysis end markets more than offsetting the continuing weakness in life science. \n Advanced Technologies , representing 34% of revenue and 7% of Group profit , has delivered strong double digit revenue growth as our compound semiconductor business continued to increase returns from its new state-of-the-art facility, while our quantum business, Oxford Instruments NanoScience,  returned to profitability as a result of cost savings and the first installations of an ongoing programme for a key global technology customer. Together, these actions have resulted in a strong increase in CC margins in the division to 4.5% (2024: 0.9%). \n We have this week exchanged contracts to sell NanoScience to Quantum Design, International Inc for a £60m total consideration, including up to £3m of deferred consideration linked to growth in quantum scaling systems . The divestment will enable the Group to focus its capital deployment on business capabilities with higher margin and potential to create shareholder value. \n The sale, which is expected to complete in the third quarter of FY2025/26, is also consistent with our focus on our three core markets: materials analysis, semiconductor, and healthcare and life science \n For further details on each division's performance, see the divisional overviews below. \n The delivery of our operational transformation programme has also enabled us to identify further growth and margin opportunities, which we are already capturing in FY2025/26, giving scope to build on progress already made. \n Across both divisions, we have reduced the cost base, with a 70bps improvement in both gross profit margin and operating profit margin. Further efficiencies are anticipated across the Group as we continue with our operational programme, and with the ongoing streamlining and simplification of processes. Strong management of inventory has contributed to an improvement in cash conversion in both divisions, with a strong net cash balance of £84.4m after £15.4m acquisition consideration , up from £39.3m at the half year. The strength of our balance sheet and the returns to come from the sale of NanoScience enable us to return capital to our shareholders via a share buyback, to commence shortly. \n Driving a step change in operational performance and productivity \n Alongside our actions to streamline and simplify Oxford Instruments, we have continued with our operational transformation programme, beginning at our Imaging & Analysis facility in Belfast and our quantum facility in Oxfordshire. The programme seeks to improve our customers' experience and drive a step change in operational performance and productivity, ultimately putting all the Group's manufacturing sites on to a much stronger operational footing. We have introduced leaner processes, improved quality and lead times, and transformed planning and forecasting. As the programme progresses, an increasing number of colleagues are upskilled, with team members subsequently deployed to further sites to pass on their learning. \n ·    The first wave of the programme, in the Belfast camera lines, has boosted camera output by more than half, from a smaller direct workforce, as well as delivering a significant improvement in first time pass rates through the build process. Wave one revealed further scope for quality improvements and efficiencies than had been anticipated, with work continuing as we go through FY25/26. A facility-wide product review in April 2025, as part of wave two of the programme, focused on systems, and has identified a small number of product lines where high material costs, heavy labour requirements and poor delivery performance has led to low profitability and questions over the competitiveness and potential of these products. Having considered performance improvement actions and potential returns, we will be discontinuing those which are a drag on the business, taking out the related cost, and refocusing our efforts on products with core leading technology with strong market potential, and alternative commercial strategies to create value. Together with improvements already made, and with new leadership, we expect to see significant further opportunity for growth and margin enhancement for this facility. \n ·    Wave two of the programme is also under way at our Advanced Technologies quantum facility in Oxfordshire, targeting productivity, quality, lead time and cost engineering improvements on the Proteox suite of cryogenic dilution refrigerators, the facility's leading product range. \n ·    Our Raman facility in Ulm, Germany, will be the subject of wave three, beginning in July, helping the facility to scale to meet growing demand.  \n The impact of the programme to date is clear, and we will continue to roll it out to further sites. \n Execution of our regional pivot \n Our actions to rebalance our regional focus, by moving the sales force to address less sensitive commercial customers in China, and strengthening our presence elsewhere in Asia, and in North America, have contributed to the Group's strong revenue growth. Growth in Europe, East and Southeast Asia and North America have more than offset the reduction in revenue in China resulting from our pivot away from sensitive quantum and certain semiconductor applications, and the ensuing cancellation of orders. \n Our pivot in China is now complete, and the local team have delivered 8% year-on-year growth in orders by targeting structurally growing commercial markets. Our recovery in the country has been supported by cross-training sales and service teams on multiple products, in combination with strong representation in key territories. \n All regions are now focusing their marketing and sales efforts around a targeted, customer segment-based approach, rather than a product-first approach. This is particularly beneficial in the Imaging & Analysis division, where we take an increasingly product-agnostic approach, offering a whole suite of analysis techniques to help customers deliver the outcomes they need for their specific use cases. \n Bolstering the bench strength of the Americas team, and investing in more effective marketing channels, has resulted in strong double digit revenue growth for the region and a 20% increase in sales per head. With a strong pipeline of qualified opportunities, ongoing activities to optimise revenue and profitability, and supportive engagement with customers on tariffs, the team is agile, close to its customers and well placed to mitigate the impacts of the new US administration's positioning on tariffs and academic funding. \n Strong revenue growth of 25% CC in East and Southeast Asia has been supported by the consolidation of separate teams for Japan, East and Southeast Asia, and Australia under one leadership team, with shared processes and increasingly aligned approaches to segmentation, as set out above. Revenue growth in the region has stemmed largely from strong semiconductor sales as customers move their operational capability out of China and new investment increases in the region. The growth is broadly split between materials analysis capabilities and compound semiconductor fabrication equipment and was able to completely offset the £20.2.m reported reduction in China resulting from the decision to exit selling of certain sensitive technologies in that territory. \n We are continuing to share best practice and streamline processes in our regional sales and marketing structures and anticipate generating further productivity benefits as we do so. \n Positioned in structurally growing markets \n Materials analysis , semiconductors and healthcare & life science remain our three primary markets. They all have high structural growth potential. Quantum technology , a much smaller contributor to our current revenue, also represents a growth opportunity, primarily within our Advanced Technologies division. This has begun to crystallise this year, although the trajectory of the quantum computing market remains less clear. \n The strategic priorities within each division reflect our decision to focus our product development and marketing activities on addressing these structurally growing markets. \n We have delivered strong year-on-year revenue growth in semiconductors , up 16.4% CC to £144.8m, generated from both divisions, with a roughly 60/40 split between our growing Advanced Technologies compound semiconductor business and our Imaging & Analysis capabilities. As semiconductor design and manufacture reshoring programmes take place, customers are increasingly using our Imaging & Analysis tools for quality control in final assembly, among other tasks. In Advanced Technologies, our fabrication equipment is used to accelerate the development of next generation semiconductor capabilities which are fundamental to enable advances in technology, including AI chips, augmented reality, 3D sensing and the hyperscale data centres needed to support growing demand for data. \n As well as advancing our customers' capabilities, we play a vital role in supporting the delivery of more good quality wafers at a lower cost per wafer. \n Materials analysis has continued to grow steadily and remains the largest end market for the Group, with revenue of £203.7m, up 3.4% CC, as customers use our technology to understand, improve and test the properties of materials across a wide range of markets, from development of structural materials and polymers to quality control in automotive and food industries. \n Growth in these markets has more than offset continued weakness in healthcare & life science , which has seen an 11.6% CC reduction in revenue year on year due to the dual headwind of original equipment manufacturers (OEMs) pausing deliveries to use existing stocks built up during the Covid pandemic, and overall sales of microscopes slowing in response to wider market dynamics, as we indicated at H1. Demand has stabilised, with order demand flat between the second half and the first half of FY25, and book to bill for the year ending at 1.O2. \n Revenues from other markets have seen a 44.6% CC increase to £73.8m, largely derived from quantum applications. This included the first installations under a key ongoing quantum partnership for Advanced Technologies, which were the key drivers of this significant growth. \n Overall demand remained positive throughout the year with 3% growth in orders at constant currency.  The order book provides visibility consistent with prior years at Oxford Instruments. Imaging and Analysis has c.5 months of order cover for FY26 and had a underlying book to bill of 1.0x in FY25 excluding China cancellations.  Advanced Technologies has c.9 months of order cover for FY26 and a book to bill of 0.9x in FY25 excluding China cancellations, reflecting the normal lumpiness in quantum orders in Advanced Technologies. Our pipeline of new opportunities is strong, whilst acknowledging the increased timing uncertainty given macro conditions. \n Focusing on our key strengths \n We have maintained levels of investment in R&D at 8.2% (2024: 8.3%) and launched new products in every part of our business, recognising that our differentiated technology is a key source of strength. The principles of maintaining and developing new leading-edge capabilities, combined with increasing ease of use, are common to the whole Group's R&D programme. As we develop our combined innovation roadmap for the Imaging & Analysis division, we are applying an increasingly commercial lens to the investments we make, to ensure that new products address a genuine gap in the market, are cost-effective to manufacture and can generate an attractive profit margin. We will also limit the number of custom builds we produce, recognising that modular, repeatable assembly benefits both productivity and profitability. \n In Imaging & Analysis, new semiconductor-specific capabilities in Raman and atomic force microscopy have gained significant traction, while our tools for electron backscatter diffraction microscopy have proved popular with industrial customers. A number of OEMs have integrated our products into their own new ranges. \n In Advanced Technologies, the first installations of our largest modular dilution refrigerator and the increasing adoption of our latest atomic layer deposition equipment for compound semiconductor have significantly contributed to growth. \n At a Group level, commercial customer revenues have increased as a proportion of total Group revenues, with our focus on growing our presence in this much larger market driving double digit growth. Revenue from academic customers, who remain the bedrock from which our commercial growth stems, was broadly flat year on year. \n   \n Ima g in g & Anal y sis \n The Imaging & Analysis division develops and manufactures microscopes, scientific cameras, analytical instruments and software, with manufacturing bases in the UK (High Wycombe and Belfast), Europe (Aix-en-Provence, Ulm and Zurich) and the USA (Santa Barbara).   \n Key highlights  \n \n \n \n \n Imaging & Analysis \n \n \n 2025   \n \n \n 2024  \n \n \n growth \n \n \n OCC growth 1 \n \n \n \n \n    \n \n \n     \n \n \n \n \n \n    \n \n \n    \n \n \n \n \n Orders  \n \n \n £318.6m  \n \n \n £306.6m  \n \n \n +3.9% \n \n \n +3.0%  \n \n \n \n \n Revenue  \n \n \n £330.5m  \n \n \n £328.1m  \n \n \n +0.7% \n \n \n +0.2%  \n \n \n \n \n Adjusted 2 operating profit  \n \n \n £76.2m  \n \n \n £79.0m  \n \n \n (3.5%) \n \n \n +2.8%  \n \n \n \n \n Adjusted 2 operating margin  \n \n \n 23.1%  \n \n \n 24.1%  \n \n \n (100bps) \n \n \n \n \n \n \n \n OCC adjusted 2 operating margin  \n \n \n 24.7%  \n \n \n 24.1%  \n \n \n \n \n \n  +60bps \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n Statutory operating profit  \n \n \n £40.8m  \n \n \n £69.2m  \n \n \n \n \n \n \n \n \n \n \n Statutory operating margin  \n \n \n 12.3%  \n \n \n 21.1%  \n \n \n \n \n \n \n \n \n \n \n   \n 1.     For definition refer to note above.   \n 2.         Details of adjusting items can be found in note 2 to the financial statements.   \n   \n Imaging & Analysis market dynamics \n Created in 2024, the Imaging & Analysis division maintains strong positions in each of our three core markets: materials analysis, semiconductors and healthcare & life science, due to our differentiated product ranges and ongoing investment in innovation. Notably strong growth in semiconductor and growth in materials analysis more than offset the continued weakness in the healthcare and life science market. \n The division supports silicon semiconductor development and production, where the breadth of our capabilities across the lifecycle, from supporting early-stage academic research through to quality assurance and failure analysis in production settings, provides resilience to cyclicality in the silicon semiconductor market. Specific semiconductor editions of our Raman microscope (capable of analysing 300mm wafers) and our atomic force microscope have helped us to increase traction in the commercial sector, with both technologies enabling customers to work on new capabilities and maintain and enhance wafer quality. \n Divisional revenue from semiconductors was up 35% CC, with orders up by a similar amount at 32% CC. This reflects strong continued demand for our highly differentiated product suite, as new applications are creating growth opportunities for electron microscopy, coupled with companies establishing new product manufacturing lines across Asia, Europe and the USA. \n Materials analysis applications also performed well, with orders up 8% CC on the year, with strong growth in structural materials R&D, commercial applications in nuclear and solar energy, and the development of new, advanced materials such as graphene and other 2D materials, where our ability to analyse at the nanoscale is key. We also saw strong growth in sales to service labs for core facilities, centralised shared resources where cutting-edge equipment is made available for scientists to carry out a wide range of analysis. Here, as elsewhere, the ease of use, accuracy and speed of the results generated by our tools are key differentiators. \n In terms of technology adoption, both Raman and electron backscatter diffraction (EBSD) products have achieved strong growth year on year. EBSD has gained particular traction with industrial customers, such as a tier 1 automotive manufacturer in China which is using our product to speed the development of faster charging EV batteries. The addition to our portfolio of nanoindentation, a technique which enables customers to test the hardness of materials, with the acquisition of FemtoTools, has also contributed to revenue growth across both semiconductor and materials analysis. \n The weakness in the healthcare & life science market continued in the second half of the year, with full-year revenue 12% CC below a strong prior year comparator. This downturn primarily reflects a reduction in imaging revenue, together with OEM and wider destocking, and is concentrated largely on our Belfast microscopy and scientific cameras facility, where historic operational challenges have been an additional factor in the reduction in revenue. Healthcare & life science orders reflect similar weakness, ending the year 8% CC down versus the prior year, lower than anticipated at half year, with some customers in the US deferring orders in the final quarter due to the actions of the US administration. However, demand has stabilised, with orders broadly flat across both halves of the year and book to bill at 1.02. \n Revenue from our Imaris software remained strong, while Raman microscopy for life science has delivered strong double-digit growth, generating 8% of divisional life science revenue (up from 4% last year). \n Overall, the division has made significant progress in growing revenue to industrial customers (up 12% CC year on year), in line with our strategic ambition to extend our reach in the much larger commercial R&D and production sector. Academic revenue was marginally down year on year. \n Strategic and operational progress \n The newly created division brings together a suite of product lines with strong synergies and a track record of success, manufactured from six sites across the UK, Europe and the US which were previously run as separate business units (including FemtoTools, acquired at the start of the year). Focused on small-scale imaging and analysis equipment and software, they share common business models, go to market strategies and margins, and address a similar client base in their three key markets in materials analysis, semiconductors, and healthcare & life science. We therefore saw a clear opportunity to enhance growth and profitability, taking the businesses in the division from good to great, by simplifying our operating model and maximising existing synergies through greater collaboration. \n Over the course of the year, we have integrated five materials analysis businesses under one leadership team. This has facilitated a degree of delayering, resulting in £1.9m of cost efficiencies as well as streamlining processes. We have also developed a shared innovation roadmap for the division, enabling us to target new product development based on the Group's strategic goals rather than at a business unit level. \n The realignment and integration programme has enabled us to more effectively realise the potential of our recent acquisitions, most notably the WITec business, acquired in 2021, which specialises in Raman microscopy. Raman product lines have delivered strong double digit revenue growth year on year, and almost 50% growth in orders, concentrated on semiconductor and life science applications. Our bolt-on acquisition in June of nanoindentation specialist FemtoTools has brought a new complementary technique to the Group's portfolio and is performing to plan, while First Light Imaging, acquired in the prior year, has been integrated with our cameras and microscopy business, extending its capabilities, notably in high speed, low noise and infrared scientific cameras. Both of our most recent acquisitions have now launched their first products under the Oxford Instruments brand. \n We see opportunities to achieve even closer integration across the Imaging & Analysis division and are actively pursuing these in FY2025/26. A further key focus for the division has been the two waves of our operational transformation programme focused on cameras and systems in Belfast, details of which are set out above. \n Our strategic actions to consolidate and streamline the division's product lines, and to embark on our operational excellence programme, have underpinned a strong divisional performance, with growth in revenue, profit and orders. We were particularly pleased to have extended Imaging & Analysis' excellent operating profit margin by 60 basis points to 24.7% OCC, at the upper end of our medium-term target range for the division. We were able to deliver this strong margin growth despite the weakness in the division's life science market, and having identified the limited profitability of a small number of product lines, primarily in Belfast, which is now being addressed. \n Advanced Technologies \n The Advanced Technologies division develops and manufactures compound semiconductor fabrication capital equipment (Severn Beach, UK), cryogenic and superconducting magnet technology (Oxford, UK), and X-ray tubes (Scotts Valley, USA).   \n Key highlights  \n \n \n \n \n Advanced Technologies \n \n \n 2025 \n \n \n 2024 \n \n \n growth \n \n \n CC growth 1 \n \n \n \n \n    \n \n \n     \n \n \n \n \n \n    \n \n \n    \n \n \n \n \n Orders  \n \n \n £145.1m \n \n \n £152.5m \n \n \n (4.9%)  \n \n \n (3.3%)  \n \n \n \n \n Revenue  \n \n \n £170.1m \n \n \n £142.3m \n \n \n +19.5%  \n \n \n +21.3%  \n \n \n \n \n Adjusted 2 operating profit  \n \n \n £6.0m  \n \n \n £1.3m \n \n \n +351.1%  \n \n \n +486.5%  \n \n \n \n \n Adjusted 2 operating margin  \n \n \n 3.5% \n \n \n 0.9% \n \n \n +260bps \n \n \n \n \n \n \n \n CC adjusted 2 operating margin  \n \n \n 4.5% \n \n \n 0.9% \n \n \n \n \n \n +360bps \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n Statutory operating profit/(loss)  \n \n \n (£0.7m)  \n \n \n £2.2m \n \n \n \n \n \n \n \n \n \n \n Statutory operating margin  \n \n \n (0.4%) \n \n \n 1.5% \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 1.     For definition refer to note on page 3. \n 2.     Details of adjusting items can be found in note 2 to the financial statements.  \n   \n The two larger businesses in Advanced Technologies each benefit from a dedicated, focused approach to reflect their specialist markets (compound semiconductor and quantum), unique growth drivers and principally separate customer bases. The division has a different profile from Imaging & Analysis, selling much lower product volumes of larger-scale complex systems. \n Our strategic priorities for Advanced Technologies are to 'fix, improve and grow', leveraging the well-invested base in both key businesses, delivering improved margins and growing our commercial customer revenues. Both businesses have made good progress following our targeted actions, resulting in strong growth in both halves of the year. Revenue was up 21.3% CC year on year, and, as predicted, the division delivered a profitable full-year performance. \n Our compound semiconductor business continues to scale as it reaps the benefits of its new, state-of-the-art facility, which has tripled capacity to address structural growth in datacomms (including AI datacentre scaling), power electronics, and augmented reality. Strong double-digit growth in both revenue and orders reflects the business's increasing foothold in carefully diversified and profitable niches within the burgeoning compound semiconductor sector. Greater focus on fewer product lines has supported improved productivity. \n Our quantum-focused facility has delivered a good year of recovery, returning to profitability as it leveraged a reduced cost base and installed the first orders for a key global technology customer as part of a major technology demonstration programme. We have crystallised the performance improvement through the sale of the business, due to complete in the third quarter of FY2024/25. \n The division's strong growth is particularly notable in the context of our regional pivot, which saw us end new quantum sales to China and target alternative customers and applications in compound semiconductor in the country. At a divisional level, we have delivered strong growth in revenue as we gained traction in North America and East and Southeast Asia, and rebuilt our position in China, with more than 50% CC order growth year on year. \n Orders overall were slightly behind last year, reflecting the lumpy order profile of the large capital equipment typically sold in the division, and a large biannual framework order that our X-Ray Technology business received a few days into the new financial year. \n Compound semiconductor operational developments and market dynamics \n Our compound semiconductor business has completed a successful first full year at its new facility at Severn Beach, near Bristol, UK. Growth plans are firmly on track, with 13% CC growth in both revenue and orders, as the business takes advantage of the improved layout and process flow of the new site, and simplified production. A key development in the year has been the completion of the site's cleanroom, which is one of the most advanced in the world for compound semiconductor process development, and is now fully signed off and operating to ISO5 specifications. Final systems, including showcasing our Imaging & Analysis metrology capabilities, are being installed and tested. The sale of our legacy site is expected to complete in H1 of FY2025/26. \n Our exceptional high-tech facilities have increased our ability to partner with leading blue-chip manufacturers. Customer demonstrations are up 30% year on year, and our qualified pipeline of opportunities has grown by 7% year on year, with improved conversion rates. \n The business has grown revenue by successfully focusing on carefully chosen subsets within the growing compound semiconductor market where we have leading-edge capabilities, and where we are able to deploy pricing power to command a higher margin than in more standardised processes. We enable next generation device architectures for better performance, helping our industrial customers to accelerate their own growth by improving wafer performance, yield and therefore cost per wafer. \n Our market applications range from datacomms to augmented reality, next generation power electronics and quantum, the blend of which provides valuable resilience to fluctuations in any single area. This year has seen strong growth in applications for datacentres, including a significant and ongoing partnership with global advanced chips manufacturer Coherent Corp. to support Coherent's 6\" InP fab ramp in Europe and the US for AI datacentres. \n We have also successfully grown revenue from quantum applications, as customers (ranging from blue chip global technology companies to leading universities and start-ups) use our equipment to make qubits, and develop their capabilities in quantum sensing and quantum communications. \n Gallium nitride applications (GaN), which enable customers to increase power and drive efficiency, have delivered significant revenue growth over the year, with Tier 1 blue chips in Japan deploying our technology into 5G and 6G, and other customers using GaN to enable more efficient power in energy-hungry data centres. We continue to target growth in GaN power applications for the year to come. \n In silicon carbide, where we have strong capabilities but limited exposure (representing 2% of FY2024/25 orders for this facility), we have delivered modest revenue growth despite the downturn in the electric vehicle market, as customers invest in R&D for next generation silicon carbide performance. \n In tandem with the move to the new site, and the strategic decision to focus on the technologies where we have a significant competitive edge, we have also generated efficiencies by streamlining the product portfolio of this business. More than 80% of orders in the year came from sales of three core platforms - Plasma Pro, IonBeam and ALD (atomic layer deposition) - with modular assembly carried out in dedicated bays, and fewer complex and resource-hungry one-off products. \n A strengthened focus on service has also contributed to the business's growth, with service revenue up 18% CC year on year. \n Quantum operational developments and market dynamics \n We are pleased with the progress made at our quantum-focused facility, Oxford Instruments NanoScience, based just outside Oxford, with the business having achieved a return to profitability, delivering the first systems of a key commercial partnership with a globally significant technology player and benefiting from reductions in its cost base made in the first half. \n The key partnership is founded on the strength of our modular Proteox proposition, which delivers vital cooling capabilities to support the scaling of this customer's quantum computing programme. The customer has received the first of our largest Proteox QX systems to be installed anywhere in the world. \n Our products, including ongoing deliveries of our smaller Proteox MX, are key to enabling our customer to scale significantly past current cryogenic refrigeration limitations to deliver its quantum roadmap. \n A further contributor to the business's recovery in FY2024/25 was our action to address the operational challenges which have hampered growth in recent years. We made progress with productivity initiatives, and addressed supply chain management and inventory challenges which became apparent following the introduction of a new ERP system. This allowed us to strengthen output through the first half and deliver a record final quarter, with more systems shipped than in any previous period. \n As set out above, we have now agreed the sale of Oxford Instruments NanoScience to Quantum Design. The divestment will enable the Group to focus its capital deployment on business capabilities with higher margin and potential for shareholder returns, and is consistent with our focus on our three core markets: materials analysis, semiconductor, and healthcare and life science. \n Capital allocation priorities \n We have a strong balance sheet which provides good optionality for the business to support our growth aspirations. Our net cash position improved in the second half, with net cash increasing to £84.4m from £39.3m at the half year. We are committed to continuing to invest 8-9% revenue in R&D and to making targeted operational investments to support our growth, whilst also being mindful of shareholder returns, taking account of underlying earnings, dividend cover, currency movements and demands on our cash. \n Our acquisition pipeline remains healthy, and is focused on adding capabilities in Imaging & Analysis. \n Our recent acquisitions, most notably WITec and FemtoTools, have benefited from the integration of business units under Imaging & Analysis, with WITec's performance notably accelerating during the year. \n We will continually assess the appropriateness of additional returns to shareholders in the form of dividends and/or buyback of the company's shares, such as the programme announced this week. \n Positive impact and progress to net zero \n The markets we serve are carefully chosen to support the development of a more sustainable planet. Our products support a range of positive outcomes, from enabling the development of personalised treatments for cancer to facilitating the path to decarbonisation through our extensive role in the battery ecosystem. We are equally committed to running our own operations sustainably.  \n We took an important step forward this year, securing validation and approval from the Science-Based Targets initiative of our science-based near and long-term targets, through which we have committed to reach net zero across our whole value chain by 2045, and to tackle our Scope 1 and 2 emissions even earlier, by 2030. \n Our targets are stretching, putting our goal five years ahead of the UK government's own commitment. Given our purpose, to accelerate the breakthroughs that create a brighter future for our world, and the contribution our technology makes to developing sustainable solutions to global challenges, I have every confidence in the commitment and talent of the Oxford Instruments team to deliver them. \n Our commitment to operating sustainably also encompasses the social impact we have on our employees and our communities, and our ethical approach to doing business. We reconfirmed our approach to each of these areas through the launch of a new Code of Conduct in November 2024, and via a new rolling programme of enhanced and extended compliance training. \n Talented global workforce addressing strategy \n The strong progress we have made this year has been driven by the energy and expertise of our highly engaged global team, who have embraced our new strategic priorities and addressed them at pace. I would like to extend my sincere thanks to all my colleagues for their commitment and agility, as we streamline and simplify Oxford Instruments and transform our operational capabilities to meet our full potential. Amid the additional context of a challenging external landscape, they have maintained strong focus and demonstrated their ability to adapt and thrive in new circumstances. \n Our first externally benchmarked global employee survey saw Oxford Instruments rated by Best Companies as 'One to Watch', recognising that this is a good place to work. While we are pleased with this outcome, especially in a year of transition, we will use it as a spur to enhance our progress in future years. \n A new chapter for NanoScience \n I would also like to take this opportunity to thank our departing colleagues in NanoScience for the contribution they have made to Oxford Instruments and the global scientific community with their advances in cryogenics and advanced magnet technology over many years. Their talent and innovative spirit are remarkable, and the Board and I wish them every success as they begin a new chapter with Quantum Design. \n Leadership changes \n I am delighted to welcome Paul Fry, who joined Oxford Instruments in January 2025, and took up the role of Chief Financial Officer on 1 April 2025, joining the Board as an Executive Director on the same date. I have greatly enjoyed working and travelling with Paul over recent months, visiting several of our international sites together as we develop our plans to unlock the full potential of Oxford Instruments. I look forward to building a strong and close partnership with him in the months and years to come. \n Gavin Hill stepped down as Chief Financial Officer and Executive Director at the end of the financial year (31 March 2025), and leaves Oxford Instruments this month. Gavin was an excellent steward of the company's finances and is enormously well respected and liked by both colleagues and stakeholders. On a personal note, I am very grateful to Gavin for his support for me when I joined the company, and wish him the very best for the future. \n Through the year we have further strengthened our capabilities through recruitment and internal promotions, including the permanent retention of our Chief Transformation Officer as Chief Operating Officer for the Group and the appointment of an internal candidate to the role of Managing Director for the Imaging & Analysis division.   \n Summary and outlook \n The Group has had a good year, reporting strong revenue, profit growth, and constant currency margin progression. It was also a year of significant progress with our strategic initiatives to improve our operational and commercial outcomes. We have turned around the profitability of our NanoScience business, and subsequently crystallised an attractive value through the sale of the business for £60m, announced this week. The sale is in line with our strategy to focus and invest in the best areas of opportunity to grow the Group and create value for shareholders, and accelerates our progress to our medium-term margin targets. I am really pleased with the agility and performance of the whole Oxford Instruments team as they have responded to the new strategy and navigated the current market environment. \n This year's results demonstrate the benefits of the long-term drivers of our business model, founded on the growth dynamics in the markets where we operate, and the demand for our market-leading products and solutions. Looking ahead, whilst acknowledging the level of macro uncertainty, we have a strong and more focused business; there is a lot we can control, and we are well placed to mitigate any direct impact from tariffs. There are further benefits to be realised from our strategic initiatives to transform the business, and our revenue visibility is healthy. Our strong balance sheet, and the proceeds to come from the sale of our quantum business, allow us to return capital to shareholders via a share buyback that we have also announced this week. We are confident that our differentiated higher margin business will continue to deliver attractive profitable growth. \n RICHARD TYSON \n Chief Executive Officer \n 12 June 2025 \n   \n Finance review \n   \n The business made a very positive step forward towards its medium-term financial goals, with organic constant currency revenue growth in the target range, and both divisions showing margin progression and improved cash conversion. Focused deployment of the strategy has offset challenging market conditions in life sciences and the pivot in China. \n \n  Key highlights \n \n \n \n \n   \n \n \n Adjusted 1 \n \n \n Statutory \n \n \n \n \n   \n \n \n   \n \n \n \n \n \n OCC 2 \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n FY25 \n \n \n FY24 \n \n \n Change \n \n \n FY25 \n \n \n FY24 \n \n \n Change \n \n \n \n \n Revenue \n \n \n £500.6m \n \n \n £470.4m \n \n \n +6.5% \n \n \n £500.6m \n \n \n £470.4m \n \n \n +6.4% \n \n \n \n \n Operating profit \n \n \n £82.2m \n \n \n £80.3m \n \n \n +10.8% \n \n \n £39.2m \n \n \n £68.3m \n \n \n (42.6%) \n \n \n \n \n Profit before tax \n \n \n £83.4m \n \n \n £83.3m \n \n \n +8.3% \n \n \n £39.8m \n \n \n £71.3m \n \n \n (44.2%) \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n Operating margin \n \n \n 16.4% \n \n \n 17.1% \n \n \n (70) bps \n \n \n 7.8% \n \n \n 14.5% \n \n \n (670) bps \n \n \n \n \n Operating margin organic CC \n \n \n 17.8% \n \n \n \n \n \n +70 bps \n \n \n   \n \n \n \n \n \n \n \n \n \n \n Normalised cash conversion 3 \n \n \n 89% \n \n \n 64% \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n Free cash flow 4 \n \n \n £31.6m \n \n \n £13.5m \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n Earnings per share - basic \n \n \n 112.4p \n \n \n 109.0p \n \n \n +3.1% \n \n \n 44.8p \n \n \n 87.7p \n \n \n (48.9%) \n \n \n \n \n Dividend per share \n \n \n 22.2p \n \n \n 20.8p \n \n \n +6.7% \n \n \n 22.2p \n \n \n 20.8p \n \n \n +6.7% \n \n \n \n \n Return on capital employed 5 \n \n \n 27.2% \n \n \n 29.1% \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n       \n 1 Removing the effect of adjusting items: see Note 2 for further analysis of adjusting items \n 2 Organic constant currency basis \n 3 Normalised cash conversion excludes the impact of Severn Beach capital investment \n 4 Free cash flow before acquisitions \n 5 See section 13 of the Finance Review for details of the calculation used \n   \n Certain Alternative Performance Measures (APMs) have been included within this Annual Report. These APMs are used by management and the Board to help it effectively monitor the performance of the Group as they consider that these represent a more consistent measure of underlying performance. Note 2 provides further analysis of the adjusting items in reaching adjusted profit measures. Definitions of the Group's material alternative performance measures, along with reconciliation to their equivalent IFRS measure, are included within the Finance Review. Unless stated otherwise, movements in orders, revenue and adjusted operating profit are given on an organic and constant currency (OCC) basis, removing the impact of acquisitions, disposals and currency movements in the year \n \n \n 1.    Orders \n Total reported orders grew by 1.0% (+0.9% at organic constant currency) to £463.7m. Order growth in the year was impacted by a high order intake in FY24 in our NanoScience business, related to a large quantum computing programme, the replenishment of which is not expected FY26. Organic order intake excluding NanoScience grew 2.8% CC (+0.4% reported). \n Order intake in the Imaging and Analysis (I&A) division grew 3.0% on an organic CC basis. First Light Imaging and FemtoTools were acquired into the I&A division in January and June 2024 respectively. Orders were strong in the semiconductor (+32%) and core materials analysis (+8%) markets, but were offset by declines in the healthcare and life science market in part due to general market weakness, but also due to historical operational challenges in our imaging business which have impacted order momentum in FY25. \n   \n Order intake in the Advanced Technologies (AT) division fell 3.3% CC. The high level of NanoScience orders in FY24, which are expected to replenish in FY26, provided a high comparator, and order intake growth excluding NanoScience was 2.1% CC. Order growth was also held back by cyclical ordering in our X-Ray Technology business, where FY24 orders are due to replenish on an approximately eighteen month to two year cycle. The Plasma business experienced strong order growth in FY25, with orders up 13.0% CC, driven by continued strong investment in commercial compound semiconductor R&D. \n   \n   \n 2.    Revenue \n Revenue of £500.6m (FY24: £470.4m) increased by 6.5% OCC (statutory +6.4%), which lies in the middle of the Group's target range of 5-8% organic growth. The cancellation of China orders in FY24 due to UK export restrictions and the Group's pivot toward lower risk customers, has resulted in CC revenues being £18.7m lower in China than FY24. This pivot is complete and China revenues are expected to return to growth in FY26. Revenues in our NanoScience business have grown significantly in FY25 (+£20.9m CC), largely due to the shipping of a number of large quantum computing systems during the year. Organic CC revenue growth excluding NanoScience and China revenues was 9.4%. \n Revenues in the academic sector fell 4.5% CC (statutory -6.4%) and have been impacted largely by the loss in China revenues described above. Non-China academic revenues grew +4.1% CC. US academia, which accounted for approximately 12% of FY25 revenue, grew +0.8% CC mainly due to a slowdown in healthcare and life science sales. US academic grew 8.7% CC excluding healthcare and life sciences revenues. Commercial applied R&D grew very strongly as commercial customers continued to invest strongly in new product and technology developments. Revenues from this sector grew 24% CC, and excluding NanoScience grew 13% CC. Revenues from commercial production and testing applications grew 7% CC. \n The Imaging and Analysis (I&A) division accounts for around 66% of Group revenue, and grew 3.1% (Statutory +0.7%). There was strong growth across the portfolio of product ranges, including SEM detectors and Raman systems, and good market acceptance of price increases. These gains were partially offset by declines in the healthcare and life sciences sector, in part due to general market weakness, but also due to historical operational challenges in our Belfast-based imaging business which have impacted performance in FY25. Divisional revenue has also been impacted by cancelled orders in China (-£7.6m versus FY24). Organic CC growth excluding China remained solid at 3.4%. \n The Advanced Technologies (AT) division grew revenue by 21.3% (statutory +19.5%) benefitting from strong demand for its plasma products and the revenue pull through of NanoScience quantum orders placed in FY23 and FY24. AT revenues were also impacted by the cancellation of orders for the China market in FY24, due to UK export licence restrictions (-£11.1m versus FY24). Excluding NanoScience and China, AT revenues grew at 29.0% CC, driven by a significant step up in plasma equipment shipments. \n   \n \n \n \n \n £m \n \n \n Imaging & Analysis \n \n \n Advanced Technologies \n \n \n Total \n \n \n \n \n Revenue: 2024 \n \n \n 328.1 \n \n \n 142.3 \n \n \n 470.4 \n \n \n \n \n Constant currency growth \n \n \n 10.1 \n \n \n 30.3 \n \n \n 40.4 \n \n \n \n \n Currency \n \n \n (7.7) \n \n \n (2.5) \n \n \n (10.2) \n \n \n \n \n Revenue: 2025 \n \n \n 330.5 \n \n \n 170.1 \n \n \n 500.6 \n \n \n \n \n \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n Revenue growth: reported \n \n \n +0.7% \n \n \n +19.5% \n \n \n +6.4% \n \n \n \n \n Revenue growth: organic constant currency \n \n \n +0.1% \n \n \n +21.3% \n \n \n +6.5% \n \n \n \n \n   \n Geographic revenue growth \n On a geographical basis, the US is now the Group's largest market, accounting for 28% of revenues. Growth has been strong in the US, up 30% OCC, due to both NanoScience revenues, and strong semiconductor performance for both plasma and materials research tools. US growth excluding NanoScience was +11% OCC. \n Whilst China revenue growth suffered from order cancellation in FY24, markets in the rest of Asia, notably Japan, South Korea, Singapore and Taiwan, have shown significant growth. Europe growth at 1.9% CC has been held back by a high comparator year in FY24 in the UK, whereas key markets such as Germany, France, Italy and the Netherlands have all shown double digit growth. \n \n \n \n \n \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n 2025 \n £m \n \n \n 2024 \n £m \n \n \n   \n Change \n \n \n Change CC \n \n \n \n \n United States 1 \n \n \n 142.3 \n \n \n 111.7 \n \n \n +27.4% \n \n \n +29.6% \n \n \n \n \n China \n \n \n 107.2 \n \n \n 127.4 \n \n \n (15.9%) \n \n \n (14.7%) \n \n \n \n \n Asia (ex. China) \n \n \n 112.7 \n \n \n 94.1 \n \n \n +19.8% \n \n \n +23.4% \n \n \n \n \n Europe \n \n \n 115.8 \n \n \n 116.1 \n \n \n (0.3%) \n \n \n +1.9% \n \n \n \n \n Rest of World \n \n \n 22.6 \n \n \n 21.1 \n \n \n +7.1% \n \n \n +8.5% \n \n \n \n \n   \n \n \n 500.6 \n \n \n 470.4 \n \n \n +6.4% \n \n \n +6.5% \n \n \n \n \n 1 CC growth excluding NanoScience +11.3% \n   \n 3.    R&D \n Total R&D expenditure charged to the income statement in the year was £41.1m, equivalent to 8.2% of sales (FY24: £39.1m; 8.3% of sales). In addition, a further £1.5m of R&D expense was capitalised (FY24 £0.7m). \n 4.    Adjusted operating profit and margin \n Adjusted operating profit of £82.2m (FY24: £80.3m) represents organic constant currency growth of 10.8% (statutory +2.4%). Adjusted operating profit margin was 16.4% (FY24: 17.1%). On an organic constant currency basis adjusted operating margin was 17.8%, up 70 bps versus the prior year. \n The I&A division represents 93% of the Group's adjusted operating profit, and it has continued to deliver a strong margin, despite the challenges in the life sciences market and imaging business, increasing its OCC margin by 60 bps to 24.7% (Statutory 23.1%). This performance is driven by a combination of product mix, price increases, and overhead cost reductions. \n The AT division improved profitability substantially in FY25. Adjusted operating profit for the division was £6.0m, up from £1.3m in FY24 and a significant reversal from the loss of £2.0m reported in H1. Profitability has benefited from the operational leverage associated with higher volumes in both the Plasma and NanoScience businesses, as well as by a focus on cost, operational improvements, and leveraging the efficiencies from the new facility in Severn Beach. As a result adjusted operating OCC margin has improved to 4.5% (FY24: 0.9%). \n   \n \n \n \n \n £m \n \n \n Imaging & Analysis \n \n \n Advanced Technologies \n \n \n Total \n \n \n \n \n Adjusted operating profit: 2024 \n \n \n 79.0 \n \n \n 1.3 \n \n \n 80.3 \n \n \n \n \n Constant currency growth \n \n \n 3.9 \n \n \n 6.5 \n \n \n 10.4 \n \n \n \n \n Currency \n \n \n (6.7) \n \n \n (1.8) \n \n \n (8.5) \n \n \n \n \n Adjusted operating profit: 2025 \n \n \n 76.2 \n \n \n 6.0 \n \n \n 82.2 \n \n \n \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n Adjusted operating margin 1 : 2024 \n \n \n 24.1% \n \n \n 0.9% \n \n \n 17.1% \n \n \n \n \n Adjusted operating margin 1 : 2025 \n \n \n 23.1% \n \n \n 3.5% \n \n \n 16.4% \n \n \n \n \n Adjusted operating margin 1 (OCC): 2025 \n \n \n 24.7% \n \n \n 4.5% \n \n \n 17.8% \n \n \n \n \n 1.             Adjusted margin is calculated as adjusted operating profit divided by revenue. Adjusted margin at constant currency is defined as adjusted operating profit at constant currency divided by revenue at constant currency. \n 5.    Adjusting items \n The following adjusting items are excluded from statutory profit in order to give a clearer picture of the underlying profitability of the Group: \n ·      Amortisation of acquired intangibles relates to intangible assets recognised on acquisitions, being the value of technology, customer relationships and brands. This value was slightly up versus the prior year at £9.2m (FY24: £9.1m). \n ·      Impairment of acquired intangibles, where the carrying value of intangible assets is not supported by forecasts of future cash flows. The Group recognised a £26.0m charge in the period, relating to the impairment of acquisition goodwill of its Andor business (see below under Balance Sheet - Intangible assets). \n ·      Non-recurring items are expenses which are considered to be exceptional in nature, and not reflective of underlying performance in the year. These costs in FY25 were £7.5m (FY24 £2.2m) and included: \n o  restructuring costs of £7.8m, of which £4.8m relating to relocation of the plasma business to Severn Beach \n o  transaction-related costs of £1.8m \n o  release of First Light Imaging contingent consideration (£2.1m) following a review of expected performance versus the earn out targets agreed at acquisition \n ·      The Group uses derivative products to hedge its short-term exposure to fluctuations in foreign exchange rates. Net movements on mark-to-market derivatives in respect of transactional currency exposures of the Group in future periods are disclosed in the Income Statement as foreign exchange and excluded from our calculation of adjusted profit before tax. In the year this amounted to a charge of £0.3m (FY24: £0.7m). \n ·      The unwind of discount in respect of contingent consideration on the acquisition of FemtoTools (£0.6m), reported under Net Finance Income. \n   \n 6.    Net finance income \n Adjusted net finance income for the Group was £1.2m (FY24: £3.0m). The reduction from last year is largely the result of lower interest income on reduced cash balances in FY25 (£1.6m; FY24 £3.2m), following capital expenditure at the Severn Beach facility and acquisitions. \n 7.    Taxation \n The adjusted tax charge of £18.2m (FY24: £20.3m) represents an adjusted effective tax rate of 21.8% (FY24: 24.4%). The tax charge of £13.8m (FY24: £20.6m) represents an effective tax rate of 34.7% (FY24: 28.9%). The decrease in the adjusted effective tax rate is due to historical transactional currency conversion adjustments related to interbranch dividend payments, as well as an increase in the rate at which the US deferred tax is recognised. We expect the adjusted effective tax rate to increase in FY26 to approximately 25.5%. \n 8.    Earnings per share \n Adjusted basic earnings per share increased by 3.1% to 112.4p (FY24: 109.0p); adjusted diluted earnings per share increased by 3.3% to 111.1p (FY24: 107.5p). Basic earnings per share decreased by 48.9% to 44.8p (FY24: 87.7p); diluted earnings per share decreased by 48.8% to 44.3p (FY24: 86.5p). \n The number of undiluted weighted average shares increased to 58.0m (FY24: 57.8m). \n 9.    Currency \n The Group faces transactional and translational currency exposure, most notably against the US dollar, euro and Japanese yen. For the year, approximately 15% of Group revenue was denominated in sterling, 51% in US dollars, 22% in euros, 9% in Japanese yen and 3% in other currencies. Translational exposures arise on the consolidation of overseas company results into sterling. Transactional exposures arise where the currency of sale or purchase transactions differs from the functional currency in which each company prepares its local accounts. \n The Group's translation and transaction foreign currency exposure for the full year 2024/25 is summarised below. \n \n \n \n \n £m equivalent \n \n \n Revenue \n \n \n Adjusted Operating Profit \n \n \n \n \n Sterling \n \n \n 72.7 \n \n \n (189.3) \n \n \n \n \n US Dollar \n \n \n 254.5 \n \n \n 179.4 \n \n \n \n \n Euro \n \n \n 108.6 \n \n \n 53.1 \n \n \n \n \n Japanese Yen \n \n \n 45.7 \n \n \n 28.2 \n \n \n \n \n Chinese Renminbi \n \n \n 7.0 \n \n \n 3.3 \n \n \n \n \n Other \n \n \n 12.1 \n \n \n 7.5 \n \n \n \n \n   \n \n \n 500.6 \n \n \n 82.2 \n \n \n \n \n   \n The headwind to operating profit is due to stronger transactional sterling currency rates against the US dollar, euro and Japanese yen exposures versus the hedged and unhedged currency rates achieved in FY24: \n \n \n \n \n £m equivalent \n \n \n FY25 blended rate \n \n \n FY24 blended rate \n \n \n % Change \n \n \n \n \n US Dollar \n \n \n 1.27 \n \n \n 1.23 \n \n \n (3.3%) \n \n \n \n \n Euro \n \n \n 1.17 \n \n \n 1.14 \n \n \n (2.6%) \n \n \n \n \n Japanese Yen \n \n \n 191 \n \n \n 173 \n \n \n (10.4%) \n \n \n \n \n   \n For the full year FY26, our assessment of the currency impact is, based on hedges currently in place and forecast currency rates, a headwind of £9.1m to revenue and £4.4m to operating profit. A one cent movement in the GBP to USD exchange rate would have an approximately £0.5m impact on adjusted operating profit. \n 10.  Balance sheet \n Intangible assets \n The Group's microscopy and scientific cameras business, Andor Technology, faced a challenging trading period as a result of continued healthcare and life science market weakness, loss of revenues in China, and operational challenges with certain product lines. Actions have been put in place to improve the performance of the business including restructuring, operational improvements and realigned commercial focus. These plans are in the early phases of execution, and therefore forecasts at 31 March 2025 for expected future cash flows from the business give greater weight to recent performance and reflect future uncertainty over the potential outcomes of those plans. Based on these forecasts it was determined that Andor's expected future cash flows at 31 March 2025 were not sufficient to support its full carrying value, resulting in a £26.0m impairment of the acquisition goodwill. \n Intangible assets net book value decreased by £16.4m versus the prior year. This decrease is largely driven by the Andor impairment and £10.6m of amortisation. This is partially offset the acquisition of FemtoTools in June 2024, adding £10.5m of intangible assets related to trademarks, technology, know-how and patents, and £9.5m of goodwill. \n Property, plant and equipment \n Additions to property, plant and equipment were £14.4m in the year. £9.2m of this was related to investment in the Severn Beach plasma facility, with £5.8m classed as assets under construction. At year-end, the total assets under construction balance was £39.0m (FY24: £33.2m). Property, plant and equipment with a carrying value of £3.6m were disposed of in the year, of which £1.8m was related to moving out of the Yatton plasma facility. The depreciation charge for the year was £5.9m. \n Working capital \n Working capital increased by £11.2m to £64.3m. The increase is mainly driven by a £9.9m reduction in FY24 customer pre-payments balances related to NanoScience quantum computing systems which were shipped in FY25, moving from trade payables to trade receivables. Trade receivables also increased due to the shipment of large equipment in the final months of the year. Inventories partially offset these movements, decreasing by £8.8m as a result of normalising inventory levels following destocking in OEMs, the burn down of the additional safety stock purchased ahead of the Severn Beach move, and other operational planning improvements. Approximately £4.2m of the trade receivables balance was related to sales to the NanoScience large quantum computing customer in Q4, which were settled by the customer in early April.  \n Pensions \n The Group has a defined benefit pension scheme in the UK. This has been closed to new entrants since 2001 and closed to future accrual from 2010. \n Scheme liabilities decreased to £194.8m (FY24: £223.6m). Company contributions of £8.7m in the period were offset by market conditions that reduced the scheme's assets during the period to £219.2m (FY24: £239.7m). On an IAS 19 basis, the surplus arising from our UK defined benefit pension scheme obligations on 31 March 2025 rose to £24.4m (FY24: £16.1m). \n The scheme's actuarial valuation review, rather than the accounting basis, determines our cash payments into the scheme. Whilst the scheme is close to self-sufficiency, the company has agreed to continue contributions until 2029. The company is expecting to contribute £9m in FY26. \n   \n 11.  Cash and liquidity \n The Group ended the year with £85.3m in cash of cash equivalents (£84.4m net cash). Adjusted cash from operations, including capital expenditure, was £65.7m (FY24: £37.6m) and represents a cash conversion of 80% (FY24: 47%). Cash conversion is calculated as adjusted cash from operations divided by adjusted operating profit. Excluding capital expenditure relating to our new semiconductor systems facility, and facility expansion in Belfast in FY24, cash conversion on a normalised basis was 89% (FY24: 64%). \n The improvement in cash conversion is mainly driven by a lower working capital increase in the year versus the prior year (FY25: +£11.4m; FY24: +£24.7m). This was partially offset by an increase in non-recurring costs of £4.9m. \n Free cash flow (FCF) has improved significantly to £31.6m in FY25 (FY24: £13.5m). This is due mainly to the improvement in cash conversion, and to the reduction in capital expenditure associated with the new Severn Beach plasma facility. FCF was used for acquisitions and to fund a dividend payment of £12.1m (FY24: £11.4m). \n   \n   \n The Group Consolidated Statement of Cash Flows is summarised below: \n \n \n \n \n   \n \n \n   \n \n \n 2025 \n \n \n 2024 \n \n \n \n \n   \n \n \n \n \n \n £m \n \n \n £m \n \n \n \n \n   \n \n \n Adjusted operating profit \n \n \n 82.2 \n \n \n 80.3 \n \n \n \n \n   \n \n \n Depreciation and amortisation \n \n \n 12.7 \n \n \n 11.0 \n \n \n \n \n   \n \n \n Adjusted EBITDA 1 \n \n \n 94.9 \n \n \n 91.3 \n \n \n \n \n   \n \n \n Working capital movement \n \n \n (11.2) \n \n \n (24.7) \n \n \n \n \n   \n \n \n Loss on disposal of plant, property and equipment \n \n \n 1.3 \n \n \n - \n \n \n \n \n   \n \n \n Non-recurring items \n \n \n (7.5) \n \n \n (2.2) \n \n \n \n \n  Equity settled share schemes \n \n \n (0.1) \n \n \n 3.0 \n \n \n \n \n   \n \n \n Pension scheme payment above charge to operating profit \n \n \n (7.9) \n \n \n (8.0) \n \n \n \n \n   \n \n \n Cash generated by operations \n \n \n 69.5 \n \n \n 59.4 \n \n \n \n \n   \n \n \n Add /(deduct): \n \n \n   \n \n \n   \n \n \n \n \n   \n \n \n Interest income \n \n \n 1.0 \n \n \n 2.2 \n \n \n \n \n   \n \n \n Tax paid \n \n \n (19.8) \n \n \n (16.1) \n \n \n \n \n   \n \n \n Capitalised development expenditure \n \n \n (1.5) \n \n \n (0.7) \n \n \n \n \n   \n \n \n Expenditure on tangible and intangible assets \n \n \n (12.1) \n \n \n (26.5) \n \n \n \n \n   \n \n \n Payments made in respect of finance leases \n \n \n (5.5) \n \n \n (4.8) \n \n \n \n \n   \n \n \n Free Cash Flow (FCF) 2 \n \n \n 31.6 \n \n \n 13.5 \n \n \n \n \n   \n \n \n Acquisition of subsidiaries, net of cash acquired \n \n \n (15.4) \n \n \n (13.4) \n \n \n \n \n   \n \n \n Dividends paid \n \n \n (12.1) \n \n \n (11.4) \n \n \n \n \n   \n \n \n Decrease in borrowings \n \n \n (0.8) \n \n \n (1.8) \n \n \n \n \n   \n \n \n Net increase/(decrease) in cash and cash equivalents \n \n \n 3.3 \n \n \n (13.1) \n \n \n \n \n   \n \n \n Effect of exchange rate fluctuations on cash held \n \n \n (3.5) \n \n \n (2.9) \n \n \n \n \n   \n \n \n Closing cash and cash equivalents \n \n \n 85.3 \n \n \n 85.5 \n \n \n \n \n   \n \n \n Borrowings \n \n \n (0.8) \n \n \n (1.8) \n \n \n \n \n   \n \n \n Net cash \n \n \n 84.4 \n \n \n 83.8 \n \n \n \n \n \n \n \n \n \n \n   \n 1 Adjusted EBITDA is defined as Adjusted operating profit before depreciation and amortisation of capitalised development costs. \n 2 Free cash flow is reported before acquisitions or similar corporate development activity \n   \n Reconciliation of cash generated from operation to adjusted operating cash flow: \n \n \n \n \n \n \n \n 2025 \n \n \n 2024 \n \n \n \n \n \n \n \n £m \n \n \n £m \n \n \n \n \n Cash generated by operations \n \n \n 69.5 \n \n \n 59.4 \n \n \n \n \n Add back /(deduct): \n \n \n   \n \n \n \n \n \n \n \n Pension scheme payment above charge to operating profit \n \n \n 7.9 \n \n \n 8.0 \n \n \n \n \n Non-recurring items \n \n \n 7.5 \n \n \n 2.2 \n \n \n \n \n Capitalised development expenditure \n \n \n (1.5) \n \n \n (0.7) \n \n \n \n \n Expenditure on tangible and intangible assets \n \n \n (12.1) \n \n \n (26.5) \n \n \n \n \n Payments made in respect of finance leases \n \n \n (5.5) \n \n \n (4.8) \n \n \n \n \n Adjusted cash generated by operations \n \n \n 65.8 \n \n \n 37.6 \n \n \n \n \n Cash conversion 1 \n \n \n 80% \n \n \n 47% \n \n \n \n \n Normalised cash conversion 2 \n \n \n 89% \n \n \n 64% \n \n \n \n \n   \n 1 Cash conversion = Adjusted cash generated by operations divided by adjusted operating profit. \n 2 Cash conversion calculated on a normalised basis excludes expenditure in the year of £7.9m (FY24: £14.1m) relating to the new semiconductor systems facility in Severn Beach in FY25 and FY24. FY24 also excludes the property acquisition in Belfast \n   \n The Group maintains an unsecured multi-currency revolving facility agreement which expires in March 2028, with two extension options. The facility is supported by four banks and comprises a euro-denominated multi-currency facility of €95.0m (£80m) and a US dollar-denominated multi-currency facility of $150.0m (£116m). \n Debt covenants are net debt to EBITDA less than 3.0 times and EBITDA to interest greater than 4.0 times. \n 12.  Dividend \n The Group's policy on the dividend takes into account changes to underlying earnings, dividend cover, movements in currency and demands on our cash. The Board remains confident in the long-term performance of the business and has proposed a final dividend of 17.1p (FY24: 15.9p) per share. This results in a total dividend of 22.2p (FY24: 20.8p) per share, growth of 6.7%. An interim dividend of 5.1p per share was paid on 7 January 2025. The final dividend will be paid, subject to shareholder approval, on 19 August 2025 to shareholders on the register as at 11 July 2025. \n 13.  Return on capital employed (ROCE) \n ROCE measures effective management of capital employed relative to the profitability of the business. ROCE is calculated as adjusted operating profit less amortisation of intangible assets divided by average capital employed. Capital employed is defined as assets (excluding cash, pension, tax and derivative assets) less liabilities (excluding tax, debt and derivative liabilities). \n Average capital employed is defined as the average of the closing balance at the current and prior year end.  \n ROCE has fallen on a reported basis to 27.1% (FY24: 29.1%), and on an organic basis, which excludes the impact of acquisitions, and Andor impairment in the year, to 26.4% (FY24: 30.6%). The fall in ROCE is due to the increase in capital employed (CE) to £268.8m from FY23 (FY24: £269.2m; FY23: £219.5m). Aside from acquisitions, the main drivers are: \n ·      the large investment in the new semiconductor systems facility in Bristol which has increased property, plant and equipment between year-end FY23 (included in the FY24 average CE value); \n ·      the significant step up in inventories in FY24 from FY23. Inventories have reduced in FY25 versus FY24, but remain at historically high levels due to increases in the level of safety stock to support the Plasma move to Severn Beach; and \n ·      increased trade receivables due to the volume of high value, large equipment shipments at year end, including the movement of NanoScience quantum computing pe-payments from trade payables to trade receivables. \n \n \n \n \n   \n \n \n 2025 \n \n \n 2024 \n \n \n \n \n   \n \n \n £m \n \n \n £m \n \n \n \n \n Adjusted operating profit \n \n \n 82.2 \n \n \n 80.3 \n \n \n \n \n Amortisation of acquired intangible assets \n \n \n (9. 2) \n \n \n (9.1) \n \n \n \n \n Adjusted operating profit after amortisation of acquired intangible assets \n \n \n 73. 0 \n \n \n 71.2 \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Property, plant and equipment \n \n \n 85.6 \n \n \n 80.5 \n \n \n \n \n Right-of-use assets \n \n \n 29.9 \n \n \n 32.4 \n \n \n \n \n Intangible assets \n \n \n 121.8 \n \n \n 138.2 \n \n \n \n \n Long-term receivables \n \n \n 1.0 \n \n \n 1.3 \n \n \n \n \n Inventories \n \n \n 99.1 \n \n \n 108.1 \n \n \n \n \n Trade and other receivables \n \n \n 126.2 \n \n \n 114.7 \n \n \n \n \n Non-current lease liabilities \n \n \n (26.7) \n \n \n (28.6) \n \n \n \n \n Trade and other payables \n \n \n (157.7) \n \n \n (166.2) \n \n \n \n \n Current lease liabilities \n \n \n (4.5) \n \n \n (4.8) \n \n \n \n \n Provisions \n \n \n (5.9) \n \n \n (6.4) \n \n \n \n \n Capital employed \n \n \n 268.8 \n \n \n 269.2 \n \n \n \n \n Average capital employed \n \n \n 269.0 \n \n \n 244.4 \n \n \n \n \n Return on capital employed (ROCE) \n \n \n 27.1% \n \n \n 29.1% \n \n \n \n \n   \n   \n   \n Return on invested capital (ROIC) \n ROIC measures the after-tax return on the total capital invested in the business. It is calculated as adjusted operating profit after tax divided by average invested capital. Invested capital is total equity less net cash, including lease liabilities. Average invested capital is defined as the average of the closing balance at the current and prior year end. Oxford Instruments aims to deliver high returns, measured by a return on capital in excess of our weighted average cost of capital of 13.4%-14.0%. ROIC has decreased in the year, due to the same key factors driving capital employed described above. \n \n \n \n \n   \n \n \n 2025 \n \n \n 2024 \n \n \n \n \n   \n \n \n £m \n \n \n £m \n \n \n \n \n Adjusted operating profit \n \n \n 82.2 \n \n \n 80.3 \n \n \n \n \n Taxation \n \n \n (18.2) \n \n \n (20.3) \n \n \n \n \n Adjusted operating profit after taxation \n \n \n 64.0 \n \n \n 60.0 \n \n \n \n \n Total equity \n \n \n 376.1 \n \n \n 365.7 \n \n \n \n \n Less: net cash and lease liabilities \n \n \n (53.2) \n \n \n (50.4) \n \n \n \n \n Invested capital \n \n \n 322.9 \n \n \n 315.3 \n \n \n \n \n Average invested capital \n \n \n 319.1 \n \n \n 295.3 \n \n \n \n \n Return on invested capital (ROIC) \n \n \n 20.1% \n \n \n 20.3% \n \n \n \n \n   \n Subsequent events \n On 10 June 2025 the Group entered into a binding agreement to sell our NanoScience business for a total consideration of £60m, of which £57m is payable on closing and up to £3m is contingent on future business performance over three years. The deal is expected to close in Q3 of FY26. \n Whilst a sale process was ongoing prior to 31 March 2025, at that point no binding offer or terms from prospective buyers had been received and therefore actions to complete the sale remained highly uncertain. In addition, management were not committed to sale and given the macro conditions prevailing at that time a successful sale remained highly uncertain. As a result, the Directors consider that the IFRS 5 conditions to classify the NanoScience assets as held for sale were not fully met. Therefore, no adjustments have been made in FY25 financial statements in respect of this potential transaction. \n Capital allocation \n The Group generated £31.6m of free cash flow in FY25, and held £85.3m in cash and cash equivalents at 31 March 2025. The Group will prioritise opportunities which deliver incremental organic growth and remains committed to a progressive dividend policy, rising in line with underlying earnings. Oxford Instruments will consider inorganic opportunities where they offer a compelling strategic and synergy case, delivering returns above the Group's financial strict criteria. Alongside this the Group will consider the buy back of its own shares where it considers there is a compelling case to create value for individual shareholders. \n In accordance with this policy the Board has approved a return of capital to shareholders of approximately £50m by means of a share buyback. In making this decision the Board has considered the current and future capital needs of the business, as well as taken into account the potential future proceeds of a sale of our NanoScience business.  \n Forward-looking statements \n This document contains certain forward‑looking statements. The forward-looking statements reflect the knowledge and information available to the company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future, thereby involving a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the company. \n PAUL FRY \n Chief Financial Officer \n 12 June 2025 \n \n Consolidated statement of income \n Year ended 31 March 2025 \n   \n \n \n \n \n \n \n \n \n \n \n 2025 \n \n \n \n \n \n 2024 \n \n \n \n \n \n \n \n \n \n \n Adjusted \n \n \n Adjusting items (Note 2) \n \n \n Total \n \n \n \n \n \n Adjusted \n \n \n Adjusting items (Note 2) \n \n \n Total \n \n \n \n \n \n \n \n \n \n \n £m \n \n \n £m \n \n \n £m \n \n \n \n \n \n £m \n \n \n £m \n \n \n £m \n \n \n \n \n Revenue \n \n \n \n \n \n 500.6 \n \n \n - \n \n \n 500.6 \n \n \n \n \n \n 470.4 \n \n \n - \n \n \n 470.4 \n \n \n \n \n Cost of sales \n \n \n \n \n \n (241.8) \n \n \n - \n \n \n (241.8) \n \n \n \n \n \n (228.0) \n \n \n - \n \n \n (228.0) \n \n \n \n \n Gross profit \n \n \n \n \n \n 258.8 \n \n \n - \n \n \n 258.8 \n \n \n \n \n \n 242.4 \n \n \n - \n \n \n 242.4 \n \n \n \n \n Other operating income \n \n \n \n \n \n - \n \n \n - \n \n \n - \n \n \n \n \n \n - \n \n \n 3.3 \n \n \n 3.3 \n \n \n \n \n Research and development \n \n \n \n \n \n (41.1) \n \n \n - \n \n \n (41.1) \n \n \n \n \n \n (39.1) \n \n \n - \n \n \n (39.1) \n \n \n \n \n Selling and marketing \n \n \n \n \n \n (78.7) \n \n \n - \n \n \n (78.7) \n \n \n \n \n \n (74.5) \n \n \n - \n \n \n (74.5) \n \n \n \n \n Administration and shared services \n \n \n \n \n \n (56.5) \n \n \n (42.7) \n \n \n (99.2) \n \n \n \n \n \n (58.7) \n \n \n (14.6) \n \n \n (73.3) \n \n \n \n \n Foreign exchange (loss)/gain \n \n \n \n \n \n (0.3) \n \n \n (0.3) \n \n \n (0.6) \n \n \n \n \n \n 10.2 \n \n \n (0.7) \n \n \n 9.5 \n \n \n \n \n Operating profit \n \n \n \n \n \n 82.2 \n \n \n (43.0) \n \n \n 39.2 \n \n \n \n \n \n 80.3 \n \n \n (12.0) \n \n \n 68.3 \n \n \n \n \n Financial income \n \n \n \n \n \n 2.6 \n \n \n - \n \n \n 2.6 \n \n \n \n \n \n 4.7 \n \n \n - \n \n \n 4.7 \n \n \n \n \n Financial expenditure \n \n \n \n \n \n (1.4) \n \n \n (0.6) \n \n \n (2.0) \n \n \n \n \n \n (1.7) \n \n \n - \n \n \n (1.7) \n \n \n \n \n Profit/(loss) before income tax \n \n \n \n \n \n 83.4 \n \n \n (43.6) \n \n \n 39.8 \n \n \n \n \n \n 83.3 \n \n \n (12.0) \n \n \n 71.3 \n \n \n \n \n Income tax (expense)/credit \n \n \n \n \n \n (18.2) \n \n \n 4.4 \n \n \n (13.8) \n \n \n \n \n \n (20.3) \n \n \n (0.3) \n \n \n (20.6) \n \n \n \n \n Profit/(loss) for the year attributable to equity shareholders of the parent \n \n \n \n \n \n 65.2 \n \n \n (39.2) \n \n \n 26.0 \n \n \n \n \n \n 63.0 \n \n \n (12.3) \n \n \n 50.7 \n \n \n \n \n \n \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n \n   \n \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Earnings per share (in pence) \n \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Basic \n \n \n \n \n \n 112.4p \n \n \n   \n \n \n 44.8p \n \n \n \n \n \n 109.0p \n \n \n \n \n \n 87.7p \n \n \n \n \n \n \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Diluted \n \n \n \n \n \n 111.1p \n \n \n   \n \n \n 44.3p \n \n \n \n \n \n 107.5p \n \n \n \n \n \n 86.5p \n \n \n \n \n   \n   \n Consolidated statement of comprehensive income \n Year ended 31 March 2025 \n   \n \n \n \n \n \n \n \n \n \n \n 2025 \n \n \n 2024 \n \n \n \n \n \n \n \n \n \n \n £m \n \n \n £m \n \n \n \n \n Profit for the year \n \n \n   \n \n \n 26.0 \n \n \n 50.7 \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Other comprehensive (expense)/income: \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n Items that may be reclassified subsequently to Consolidated Statement of Income \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n Foreign exchange translation differences \n \n \n \n \n \n (2.0) \n \n \n (5.5) \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Items that will not be reclassified to Consolidated Statement of Income \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n Remeasurement loss in respect of post-retirement benefits \n \n \n \n \n \n (1.1) \n \n \n (19.4) \n \n \n \n \n Tax credit on items that will not be reclassified to Consolidated Statement of Income \n \n \n \n \n \n 0.2 \n \n \n 4.8 \n \n \n \n \n Total other comprehensive expense \n \n \n   \n \n \n (2.9) \n \n \n (20.1) \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Total comprehensive income for the year attributable to equity shareholders of the parent \n \n \n   \n \n \n 23.1 \n \n \n 30.6 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n \n Consolidated statement of financial position \n As at 31 March 2025 \n   \n \n \n \n \n \n \n \n \n \n \n 2025 \n \n \n 2024 as restated 1 \n \n \n \n \n \n \n \n \n \n \n £m \n \n \n £m \n \n \n \n \n Assets \n \n \n   \n \n \n   \n \n \n \n \n \n \n \n Non-current assets \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Property, plant and equipment \n \n \n \n \n \n 85.6 \n \n \n 80.5 \n \n \n \n \n Intangible assets \n \n \n \n \n \n 121.8 \n \n \n 138.2 \n \n \n \n \n Right-of-use assets \n \n \n \n \n \n 29.9 \n \n \n 32.4 \n \n \n \n \n Long-term receivables \n \n \n \n \n \n 1.0 \n \n \n 1.3 \n \n \n \n \n Derivative financial instruments \n \n \n \n \n \n 0.3 \n \n \n 0.2 \n \n \n \n \n Retirement benefit asset \n \n \n \n \n \n 24.4 \n \n \n 16.1 \n \n \n \n \n Deferred tax assets \n \n \n \n \n \n 11.1 \n \n \n 13.7 \n \n \n \n \n \n \n \n \n \n \n 274.1 \n \n \n 282.4 \n \n \n \n \n Current assets \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Inventories \n \n \n \n \n \n 99.1 \n \n \n 108.1 \n \n \n \n \n Trade and other receivables \n \n \n \n \n \n 126.2 \n \n \n 114.7 \n \n \n \n \n Current income tax receivable \n \n \n \n \n \n 9.4 \n \n \n 1.0 \n \n \n \n \n Derivative financial instruments \n \n \n \n \n \n 1.9 \n \n \n 2.3 \n \n \n \n \n Cash and cash equivalents \n \n \n \n \n \n 94.1 \n \n \n 97.8 \n \n \n \n \n \n \n \n \n \n \n 330.7 \n \n \n 323.9 \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Total assets \n \n \n \n \n \n 604.8 \n \n \n 606.3 \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Equity \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Capital and reserves attributable to the company's equity shareholders \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Share capital \n \n \n \n \n \n 2.9 \n \n \n 2.9 \n \n \n \n \n Share premium \n \n \n \n \n \n 62.6 \n \n \n 62.6 \n \n \n \n \n Other reserves \n \n \n \n \n \n 0.2 \n \n \n 0.2 \n \n \n \n \n Translation reserve \n \n \n \n \n \n 5.4 \n \n \n 7.4 \n \n \n \n \n Retained earnings \n \n \n \n \n \n 305.0 \n \n \n 292.6 \n \n \n \n \n \n \n \n \n \n \n 376.1 \n \n \n 365.7 \n \n \n \n \n Liabilities \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Non-current liabilities \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Bank loans \n \n \n \n \n \n 0.5 \n \n \n 0.9 \n \n \n \n \n Lease liabilities \n \n \n \n \n \n 26.7 \n \n \n 28.6 \n \n \n \n \n Retirement benefit obligations \n \n \n \n \n \n 0.9 \n \n \n - \n \n \n \n \n Provisions \n \n \n \n \n \n 1.3 \n \n \n - \n \n \n \n \n Deferred tax liabilities \n \n \n \n \n \n 16.7 \n \n \n 12.9 \n \n \n \n \n \n \n \n \n \n \n 46.1 \n \n \n 42.4 \n \n \n \n \n Current liabilities \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Bank loans and overdrafts \n \n \n \n \n \n 9.2 \n \n \n 13.1 \n \n \n \n \n Trade and other payables \n \n \n \n \n \n 157.7 \n \n \n 166.2 \n \n \n \n \n Lease liabilities \n \n \n \n \n \n 4.5 \n \n \n 4.8 \n \n \n \n \n Current income tax payables \n \n \n \n \n \n 6.0 \n \n \n 7.6 \n \n \n \n \n Derivative financial instruments \n \n \n \n \n \n 0.6 \n \n \n 0.1 \n \n \n \n \n Provisions \n \n \n \n \n \n 4.6 \n \n \n 6.4 \n \n \n \n \n \n \n \n \n \n \n 182.6 \n \n \n 198.2 \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Total liabilities \n \n \n \n \n \n 228.7 \n \n \n 240.6 \n \n \n \n \n \n \n \n \n \n \n   \n \n \n \n \n \n \n \n Total liabilities and equity \n \n \n   \n \n \n 604.8 \n \n \n 606.3 \n \n \n \n \n 1 Details of restatement of prior period numbers can be found in Note 7. \n   \n   \n Consolidated statement of changes in equity \n Year ended 31 March 2025 \n   \n \n \n \n \n \n \n \n Share capital \n \n \n Share premium \n \n \n Other reserves \n \n \n Translation reserve \n \n \n Retained earnings \n \n \n Total \n \n \n \n \n \n \n \n £m \n \n \n £m \n \n \n £m \n \n \n £m \n \n \n £m \n \n \n £m \n \n \n \n \n As at 1 April 2024 \n \n \n 2.9 \n \n \n 62.6 \n \n \n 0.2 \n \n \n 7.4 \n \n \n 292.6 \n \n \n 365.7 \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n Profit for the year \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n 26.0 \n \n \n 26.0 \n \n \n \n \n Foreign exchange translation differences \n \n \n - \n \n \n - \n \n \n - \n \n \n (2.0) \n \n \n - \n \n \n (2.0) \n \n \n \n \n Remeasurement loss in respect of post-retirement benefits \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n (1.1) \n \n \n (1.1) \n \n \n \n \n Tax credit on items that will not be reclassified to Consolidated Statement of Income \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n 0.2 \n \n \n 0.2 \n \n \n \n \n Total comprehensive (expense)/income \n \n \n - \n \n \n - \n \n \n - \n \n \n (2.0) \n \n \n 25.1 \n \n \n 23.1 \n \n \n \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n Share-based payment transactions \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n (0.1) \n \n \n (0.1) \n \n \n \n \n Income tax on share-based payment transactions \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n (0.5) \n \n \n (0.5) \n \n \n \n \n Dividends \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n (12.1) \n \n \n (12.1) \n \n \n \n \n Total transactions with owners: \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n (12.7) \n \n \n (12.7) \n \n \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n   \n \n \n \n \n As at 31 March 2025 \n \n \n 2.9 \n \n \n 62.6 \n \n \n 0.2 \n \n \n 5.4 \n \n \n 305.0 \n \n \n 376.1 \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n As at 1 April 2023 \n \n \n 2.9 \n \n \n 62.6 \n \n \n 0.2 \n \n \n 12.9 \n \n \n 265.4 \n \n \n 344.0 \n \n \n \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Profit for the year \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n \n \n 50.7 \n \n \n 50.7 \n \n \n \n \n Foreign exchange translation differences \n \n \n - \n \n \n - \n \n \n - \n \n \n (5.5) \n \n \n - \n \n \n (5.5) \n \n \n \n \n Remeasurement loss in respect of post-retirement benefits \n \n \n - \n \n \n - \n \n \n - \n \n \n - \n ...

View stock analysis, news, and events for Oxford Instruments Plc